BioRap Technologies and Pfizer have entered a co-development agreement to improve the research and development of novel immunomodulators, which will help in introducing new treatment options for chronic autoimmune diseases.
According to the agreement, Pfizer can opt to obtain a licence to the monoclonal antibody programme and will be responsible for development and commercialisation of any resulting product.
BioRap Technologies will receive milestone-based payments and royalties for all the jointly-developed products.
Saniona AB, a biotechnology company, has acquired all rights to two drugs, namely ACR325 and ACR343, from NeuroSearch A/S to strengthen and further develop its products that are in the pipeline.
Pursuant to the agreement, Saniona will be responsible for the maintenance costs of the patent rights to ACR325 and ACR343, while NeuroSearch will receive up to 20% of all the milestones and royalties obtained during the development and commercialisation of the two drugs.
Mylan N.V. plans to raise gross proceeds of $2.25bn through private placement of 3.15% senior notes, due in 2021.
The company plans to invest the funds to acquire all outstanding shares of Meda AB to repay, prepay, redeem or refinance its debts and to pay costs associated with the acquisition of Meda.
The offer will be subscribed to by qualified institutional buyers in and outside the US to non-US persons in reliance.
Pfizer plans to raise funds from public offering of 2.75% notes due in 2026. The company intends to use part of the funds for repaying a portion of its outstanding commercial paper and partly for general corporate purposes.
Barclays Capital, Goldman Sachs & Co, J.P Morgan and Morgan Stanley are acting as book-running managers, while Skadden, Arps, Slate and Meagher & Flom are acting as the legal advisors for the offering.
The company expects to raise gross proceeds of $1.25bn from the offering.
AC Immune has filed a draft registration statement with the US Securities and Exchange Commission for the initial public offering of its common stock shares to raise gross proceeds of up to $50m.
The company plans to use a part of funds to support the advancement of clinical trials of its therapeutic and diagnostic products for Down’s syndrome, development of non-AD, non-PD programmes, morphomer and glaucoma programmes and for general corporate purposes.
Image: Pfizer plans to raise funds from public offering of 2.75% notes due in 2026. Photo: courtesy of Lauri Silvennoinen.